$BCYC
Bicycle Therapeutics PLC

2022 Q3 Form 10-Q Financial Statement

#000155837022012050 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $3.040M $4.378M $3.860M
YoY Change -29.84% 145.27% 113.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.25M $11.14M $16.85M
YoY Change 23.94% 51.7% 107.98%
% of Gross Profit
Research & Development $22.75M $19.85M $14.28M
YoY Change 116.42% 69.37% 47.36%
% of Gross Profit
Depreciation & Amortization $1.300M $600.0K $422.0K
YoY Change 333.33% 100.0% 29.85%
% of Gross Profit
Operating Expenses $32.80M $31.68M $31.24M
YoY Change 76.08% 66.18% 75.21%
Operating Profit -$29.76M -$27.30M -$27.38M
YoY Change 108.19% 58.01% 70.89%
Interest Expense $817.0K $883.0K $818.0K
YoY Change -0.73% 7.81% 56.7%
% of Operating Profit
Other Income/Expense, Net $1.174M $25.00K -$600.0K
YoY Change -246.93% -103.14% 18.34%
Pretax Income -$28.59M -$27.28M -$27.98M
YoY Change 89.39% 50.92% 69.28%
Income Tax -$200.0K -$400.0K -$400.0K
% Of Pretax Income
Net Earnings -$28.30M -$26.80M -$27.56M
YoY Change 92.52% 49.72% 70.24%
Net Earnings / Revenue -930.92% -612.15% -714.09%
Basic Earnings Per Share -$0.96 -$0.90 -$0.93
Diluted Earnings Per Share -$0.96 -$0.90 -$0.93
COMMON SHARES
Basic Shares Outstanding 29.68M 29.65M 29.61M
Diluted Shares Outstanding 29.68M 29.65M 29.61M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $361.5M $372.8M $407.4M
YoY Change 39.28% 87.57% 107.95%
Cash & Equivalents $361.5M $372.8M $407.4M
Short-Term Investments
Other Short-Term Assets $8.448M $9.454M $9.067M
YoY Change 49.68% 97.29% 51.12%
Inventory
Prepaid Expenses
Receivables $0.00 $10.00M $0.00
Other Receivables $11.37M $16.27M $13.33M
Total Short-Term Assets $381.3M $408.5M $429.8M
YoY Change 39.73% 87.56% 99.52%
LONG-TERM ASSETS
Property, Plant & Equipment $16.22M $16.82M $8.849M
YoY Change 565.57% 614.62% 40.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.159M $5.098M $4.198M
YoY Change 121.71% 114.29% 90.82%
Total Long-Term Assets $35.86M $36.99M $29.80M
YoY Change 323.86% 347.81% 254.73%
TOTAL ASSETS
Total Short-Term Assets $381.3M $408.5M $429.8M
Total Long-Term Assets $35.86M $36.99M $29.80M
Total Assets $417.1M $445.5M $459.6M
YoY Change 48.28% 97.07% 105.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.057M $4.859M $3.999M
YoY Change 300.74% 39.99% 299.9%
Accrued Expenses $18.09M $16.95M $12.27M
YoY Change 65.17% 53.23% 27.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.55M $41.34M $35.41M
YoY Change 37.69% 77.64% 70.26%
LONG-TERM LIABILITIES
Long-Term Debt $30.23M $30.14M $30.01M
YoY Change 1.61% 1.74% 1.72%
Other Long-Term Liabilities $3.157M $3.260M $3.362M
YoY Change 3.81% 10.1% -89.29%
Total Long-Term Liabilities $33.39M $33.40M $33.37M
YoY Change 1.81% 2.5% -45.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.55M $41.34M $35.41M
Total Long-Term Liabilities $33.39M $33.40M $33.37M
Total Liabilities $127.7M $134.1M $129.3M
YoY Change 15.53% 59.63% 58.07%
SHAREHOLDERS EQUITY
Retained Earnings -$301.1M -$272.8M -$245.9M
YoY Change 50.32% 46.9%
Common Stock $385.0K $385.0K $385.0K
YoY Change 17.02% 24.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $289.5M $311.4M $330.3M
YoY Change
Total Liabilities & Shareholders Equity $417.1M $445.5M $459.6M
YoY Change 48.28% 97.07% 105.35%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$28.30M -$26.80M -$27.56M
YoY Change 92.52% 49.72% 70.24%
Depreciation, Depletion And Amortization $1.300M $600.0K $422.0K
YoY Change 333.33% 100.0% 29.85%
Cash From Operating Activities -$5.871M -$23.53M -$26.40M
YoY Change -127.03% 90.27% 92.6%
INVESTING ACTIVITIES
Capital Expenditures -$2.984M -$9.799M $4.756M
YoY Change 1665.68% 5531.61% 663.4%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.984M -$9.799M -$4.756M
YoY Change 1665.68% 5531.61% 663.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 159.0K 195.0K 450.0K
YoY Change -99.61% -98.75% -99.39%
NET CHANGE
Cash From Operating Activities -5.871M -23.53M -26.40M
Cash From Investing Activities -2.984M -9.799M -4.756M
Cash From Financing Activities 159.0K 195.0K 450.0K
Net Change In Cash -8.696M -33.14M -31.31M
YoY Change -114.03% -1200.83% -152.26%
FREE CASH FLOW
Cash From Operating Activities -$5.871M -$23.53M -$26.40M
Capital Expenditures -$2.984M -$9.799M $4.756M
Free Cash Flow -$2.887M -$13.73M -$31.16M
YoY Change -113.19% 12.62% 117.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-38916
dei Entity Registrant Name
EntityRegistrantName
Bicycle Therapeutics plc
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24052168
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29626974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23047745
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001761612
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29648564
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24052168
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29626974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23047745
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29579364
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29666317
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
Blocks A & B
dei Entity Address Address Line2
EntityAddressAddressLine2
Portway Building, Granta Park
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34604000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3209000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-447000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-160000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-866000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-603000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
us-gaap Interest Paid Net
InterestPaidNet
1390000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-789000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Interest Paid Net
InterestPaidNet
1074000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
dei Entity Address City Or Town
EntityAddressCityOrTown
Great Abington, Cambridge,
dei Entity Address Country
EntityAddressCountry
GB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
CB21 6GS
dei City Area Code
CityAreaCode
+44
dei Local Phone Number
LocalPhoneNumber
1223 261503
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29676127
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372769000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
438680000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10000000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9454000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7965000
CY2022Q2 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
16270000
CY2021Q4 bcyc Research And Development Incentives Receivable Current
ResearchAndDevelopmentIncentivesReceivableCurrent
10910000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
408493000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
458555000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16815000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15076000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14666000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5098000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000
CY2022Q2 us-gaap Assets
Assets
445482000
CY2021Q4 us-gaap Assets
Assets
479792000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4859000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2721000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16952000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19530000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19273000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
41341000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36238000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30144000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29873000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12496000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12081000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
46849000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
52067000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3260000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3279000
CY2022Q2 us-gaap Liabilities
Liabilities
134090000
CY2021Q4 us-gaap Liabilities
Liabilities
133538000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
4982000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
749000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2418000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29666317
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29579364
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
385000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
384000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
584152000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
567637000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-374000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3388000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272771000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218379000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
311392000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
445482000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
479792000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4378000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1785000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3593000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19854000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11722000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34138000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21415000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11824000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7340000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28783000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15479000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
31678000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
19062000
us-gaap Operating Expenses
OperatingExpenses
62921000
us-gaap Operating Expenses
OperatingExpenses
36894000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27300000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17277000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54683000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33301000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
908000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
23000
us-gaap Interest And Other Income
InterestAndOtherIncome
1126000
us-gaap Interest And Other Income
InterestAndOtherIncome
38000
CY2022Q2 us-gaap Interest Expense
InterestExpense
883000
CY2021Q2 us-gaap Interest Expense
InterestExpense
819000
us-gaap Interest Expense
InterestExpense
1701000
us-gaap Interest Expense
InterestExpense
1341000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-796000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-575000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1303000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27275000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
53000
us-gaap Net Income Loss
NetIncomeLoss
-34104000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18073000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55258000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2094000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-255000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
3014000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-313000
us-gaap Net Income Loss
NetIncomeLoss
-34104000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17913000
us-gaap Net Income Loss
NetIncomeLoss
-54392000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29648564
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24052168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29626974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23047745
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17913000
us-gaap Net Income Loss
NetIncomeLoss
-54392000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24734000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18168000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51378000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34417000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
346254000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10198000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
920000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-27564000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
330258000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5673000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2094000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26828000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
311392000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
95460000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1800000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58775000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3821000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-58000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16191000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
142091000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1575000
CY2021Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13977000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2575000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-255000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17913000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
142050000
us-gaap Profit Loss
ProfitLoss
-54392000
us-gaap Profit Loss
ProfitLoss
-34104000
us-gaap Share Based Compensation
ShareBasedCompensation
15871000
us-gaap Share Based Compensation
ShareBasedCompensation
6396000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1039000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
665000
bcyc Non Cash Interest Expense
NonCashInterestExpense
271000
bcyc Non Cash Interest Expense
NonCashInterestExpense
223000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9346000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5544000
bcyc Increase Decrease In Research And Development Incentives Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable
6850000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-278000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1343000
bcyc Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
2229000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1616000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
554000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1341000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2225000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2296000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2072000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1549000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
334000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
317000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49931000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26077000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14555000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
794000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14555000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-794000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
72752000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
645000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1859000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
645000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89611000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2070000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65911000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
62748000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
438680000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135990000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372769000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
198738000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1336000
bcyc Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
200000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1209000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3120000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
372800000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26800000
us-gaap Net Income Loss
NetIncomeLoss
-54400000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17900000
us-gaap Net Income Loss
NetIncomeLoss
-34100000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, revenue recognition, share-based compensation expense, valuation of right-of-use assets and liabilities, and income taxes, including the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of reasonable changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.</p>
CY2022Q2 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
400000
bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
800000
CY2021Q2 bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
800000
bcyc Reduction Of Research And Development Expense Related To Government Grant Arrangements
ReductionOfResearchAndDevelopmentExpenseRelatedToGovernmentGrantArrangements
1900000
CY2022Q2 bcyc Remaining Government Grant Funding For Future Cost Reimbursement
RemainingGovernmentGrantFundingForFutureCostReimbursement
1700000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
200000000.0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
100000000.0
CY2022Q2 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
1000000.0
CY2021Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
700000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21995000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7923000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5180000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4800000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16815000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3123000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4554000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6429000
CY2022Q2 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
7685000
CY2021Q4 bcyc Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3980000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
850000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
882000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2905000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2383000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
958000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
570000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16952000
CY2022Q2 bcyc Debt Instrument End Of Term Charge Rate
DebtInstrumentEndOfTermChargeRate
0.050
CY2022Q2 bcyc Debt Instrument Additional Interest Rate Event Of Default
DebtInstrumentAdditionalInterestRateEventOfDefault
0.050
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q2 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
564000
CY2021Q4 bcyc Debt End Of Term Charge
DebtEndOfTermCharge
376000
CY2022Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
420000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
503000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14244000
CY2022Q2 bcyc Debt Instrument Prepayment Option Excess Of Outstanding Amount
DebtInstrumentPrepaymentOptionExcessOfOutstandingAmount
5000000.0
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
30144000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
29873000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
31500000
CY2022Q2 bcyc Long Term Debt Including End Term Charge
LongTermDebtIncludingEndTermCharge
31500000
bcyc Number Of Voter Per Share
NumberOfVoterPerShare
1
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57820181
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55295420
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6396000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5673000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2575000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15871000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
66379000
CY2021Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
1785000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
8238000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4378000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1785000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3593000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
10000000
bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
8238000
bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
6723000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35156000
CY2021 bcyc Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
49056000
CY2021 bcyc Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11697000
CY2021 bcyc Contract With Customer Liability Foreign Currency Adjustment
ContractWithCustomerLiabilityForeignCurrencyAdjustment
1175000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71340000
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2022Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3213000
CY2021Q2 bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
1405000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
7032000
bcyc Contract With Customer Liability Revenue Recognized Proportional Performance Obligation
ContractWithCustomerLiabilityRevenueRecognizedProportionalPerformanceObligation
3057000
CY2022Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1165000
CY2021Q2 bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
380000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
1206000
bcyc Contract With Customer Liability Revenue Recognized Expiration Of Material Rights
ContractWithCustomerLiabilityRevenueRecognizedExpirationOfMaterialRights
380000
bcyc Contract With Customer Liability Revenue Recognized On Changes In Transaction Price
ContractWithCustomerLiabilityRevenueRecognizedOnChangesInTransactionPrice
156000
CY2022Q2 bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
4378000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-900000
bcyc Total Revenue Recognized From Both Beginning Balance And Current Period Increase In Contract Liability
TotalRevenueRecognizedFromBothBeginningBalanceAndCurrentPeriodIncreaseInContractLiability
3593000
CY2016Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
50900000
CY2019Q4 bcyc Research And Development Arrangement Obligation To Repay Other Parties
ResearchAndDevelopmentArrangementObligationToRepayOtherParties
60300000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1036000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
273000
us-gaap Operating Lease Cost
OperatingLeaseCost
1942000
us-gaap Operating Lease Cost
OperatingLeaseCost
505000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
328000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
143000
us-gaap Variable Lease Cost
VariableLeaseCost
595000
us-gaap Variable Lease Cost
VariableLeaseCost
222000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1364000
CY2021Q2 us-gaap Lease Cost
LeaseCost
416000
us-gaap Lease Cost
LeaseCost
2537000
us-gaap Lease Cost
LeaseCost
727000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0704
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0792
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1867000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3981000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4003000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4025000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3243000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
821000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2539000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
15401000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2905000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12496000
bcyc Maximum Days Allowed For Cancellation Of Contracts Prior Written Notice
MaximumDaysAllowedForCancellationOfContractsPriorWrittenNotice
P90D
CY2022Q2 bcyc Period Of Royalty Payments Agreed Under Arrangement
PeriodOfRoyaltyPaymentsAgreedUnderArrangement
P10Y
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26828000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17913000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54392000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34104000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29648564
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24052168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29626974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23047745
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5821869
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4920831
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q2 us-gaap Noncurrent Assets
NoncurrentAssets
31891000
CY2021Q4 us-gaap Noncurrent Assets
NoncurrentAssets
17789000

Files In Submission

Name View Source Status
0001558370-22-012050-index-headers.html Edgar Link pending
0001558370-22-012050-index.html Edgar Link pending
0001558370-22-012050.txt Edgar Link pending
0001558370-22-012050-xbrl.zip Edgar Link pending
bcyc-20220630.xsd Edgar Link pending
bcyc-20220630x10q.htm Edgar Link pending
bcyc-20220630x10q_htm.xml Edgar Link completed
bcyc-20220630xex10d1.htm Edgar Link pending
bcyc-20220630xex10d1001.jpg Edgar Link pending
bcyc-20220630xex10d1002.jpg Edgar Link pending
bcyc-20220630xex10d2.htm Edgar Link pending
bcyc-20220630xex31d1.htm Edgar Link pending
bcyc-20220630xex31d2.htm Edgar Link pending
bcyc-20220630xex32d1.htm Edgar Link pending
bcyc-20220630_cal.xml Edgar Link unprocessable
bcyc-20220630_def.xml Edgar Link unprocessable
bcyc-20220630_lab.xml Edgar Link unprocessable
bcyc-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending